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Renal failure is a condition in which
many factors are involved in altering a
drug’s pharmacokinetics, inducing
changes in the absorption of the drug,
plasma protein binding, volume of
distribution, excretion, drug sensitivity
and tissue distribution.  Thus when
prescribing a drug in such a condition,
one must keep some basic principles in
mind.
Acute renal failure may be defined as
the cessation of renal excretory function
within a period of hours or days,
accompanied by a rise in serum urea and
creatinine.  It may be accompanied by a
fall in urine output, presenting itself as
anuria or oliguria.   The causes of acute
renal failure may be classified as pre-
renal, renal and post-renal damage.
Pre-renal damage occurs when the
kidneys are deprived of blood flow.
Drugs can cause this type of damage
by compromising the circulation and
hence decreasing renal perfusion.
Volume depletion resulting from
aggressive diuretic therapy or from
major gastrointestinal losses caused
by drug-induced diarrhoea and/or
vomiting can compromise renal
function.1   Renal damage may be
subdivided into vascular, glomerular,
tubular, and interstitial damage.
Post-renal damage occurs when there
is blockage to urinary outflow, for
example, in  prosthetic hypertrophy.
Drugs may be the cause of any of
these processes leading to renal
failure.  Analgesic nephropathy is a
form of renal disease in which there
is often renal papillary necrosis and a
history of analgesic administration.
Analgesic combinations seem to
increase the risk of developing
chronic tubular interstitial disease
and papillary necrosis.1  Table 1 gives
examples of such drugs.
Chronic renal disease occurs as a
result of primary renal disease or a
renal complication of another
disease, for example diabetes
mellitus.  As the kidney function
declines, the regulatory capacity of
the kidney fails and uraemic
complications occur affecting most
systems of the body.2
1. Patients with renal disease are
prone to the anaemia that may
result from uraemia and reduced
erythropoietin production.
Uraemia increases the risk of GI
bleeding.
2. Another complication is that as
renal function decreases,
phosphate filtration in kidney is
reduced, leading to high
phosphate levels (which causes
itching).  The latter results in low
plasma calcium.  A lack of active
vitamin D causes reduction in
calcium absorption from the gut
and also results in low plasma
calcium.  Low calcium levels
stimulate PTH secretion thus
releasing calcium from bones
causing renal osteodystrophy.
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  Pre-renal Drugs causing   Analgesic    Drugs causing Tubulotoxic     Drugs causing
   disease  crystalluria nephropathy glomerulonephritis     drugs interstitial  nephritis
Acetazolamide
Aciclovir
Allopurinol
Aminoglycosides
Aminosalicylates
Amphotericin
Antihypertensives
Bumetanide, Furosemide
Caffeine
Cephalosporins
Ciclosporin A
Cimetidine
Cisplatin
Cotrimoxazole
Diuretics
Gold
Halothane
Hydralazine
Ifosfamide
Indinavir
Interferon
Isoniazid
Laxatives
Lithium
Mannitol
Mercaptopurine
Methotrexate
Nitrofurantoin
NSAIDs
Paracetamol
Penicillin
Pentamidine
Phenytoin
Probenecid
Quinidine
Quinolones
Rifampicin
Salicylates
Sulphonamides
Tacrolimus
Thiazides
Vancomycin
Vasoconstrictors
Vitamin C
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Table 1: Drugs affecting renal function1
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3. Oedema results from sodium and
water retention.  Low serum
albumin is common in renal
patients and can contribute to
fluid retention.
4. The kidney’s role in monitoring the
correct ionic, osmotic, pH and fluid
balance is disturbed and control of
potassium levels deteriorates.
Hyperkalaemia can cause muscle
weakness, arrhythmias and cardiac
arrest.
5. Acidosis results from hydrogen ion
accumulation manifesting itself as
decreased bicarbonate levels.
6. Restless legs, pruritus (due to high
phosphate levels or uraemia),
nausea (accumulation of toxins)
are other complications.
The use of drugs in patients with
reduced renal failure can cause
problems.
1. The failure to excrete a drug or its
metabolites may produce toxicity.
Most systemically administered
drugs are eliminated at least partly
by the kidney, even if it is only a
tiny proportion of the administered
dose.  However for some drugs, the
kidney is the major site of
elimination of unchanged drug and
these are particularly liable to
require careful dose adjustment in
renal dysfunction to prevent
accumulation. Examples of such
drugs include aciclovir, cefotaxime,
ciprofloxacin, digoxin, electrolytes,
fluconazole, gentamicin, lithium,
meropenem, pamidronate,
methotrexate and vancomycin.3
2. There are drugs with therapeutic
activity at least partly dependent
upon metabolites that are excreted
unchanged by the kidney.3 An
examples of such a drug is
allopurinol, whose therapeutic
activity depends on the metabolite
oxipurinol, the latter being
excreted unchanged by the kidney.3
3. Nephrotoxic drugs must be
avoided.
4. Sensitivity to some drugs is
increased even if elimination is
unimpaired.  Uraemic patients are
more susceptible to drug effects,
for example an increased CNS-
depressant effect due to increased
permeability of blood brain barrier.3
5. Gastrointestinal disturbances are
very common and prescribing
antacids must be done with
caution.4
6. Some drugs may cease to be
effective when renal failure is
reduced.  In the presence of oedema
and ascites, there is an increased
apparent volume of distribution of
highly water-soluble drugs.  Higher
doses may be needed.  Conversely
dehydration or muscle wasting may
result in unexpectedly high plasma
concentrations of drug.3 Thus since
oedema is a result of sodium and
water retention, the sodium content
of drugs must be checked before
prescribing the drug.
7. Highly protein-bound drugs must be
used with caution.  This is because
plasma protein binding is decreased
in uraemia due to decreased plasma
albumin levels allowing more free
drug available at the site of action
but a shorter half-life since more
free drug can be metabolized
and/or excreted.3
Besides the problems mentioned,
some precautions must also be kept in
mind.
1. If even mild renal impairment is
considered likely on clinical
grounds, renal function should be
checked before prescribing any drug
that requires dose modification.
2. Before starting a drug for a patient
who is on dialysis, it must be
checked whether the drug is
dialysed or not.  Sometimes doses
may need to be titrated.
3. Renal function generally declines
with age and many elderly patients
have a glomerular filtration rate
(GFR) of less than 50mL/min, which
because of reduced muscle mass,
may not be reflected by an elevated
creatinine.  Thus one can assume
mild renal impairment in the
elderly.5
Consequently, when choosing a drug
for a renally impaired patient, one must
also keep the above points in mind
together with the complications that
arise in chronic renal failure.
Principles
of dosage adjustment
For toxic drugs with a small safety
margin, dosage regimens based on
glomerular filtration rate should be
used.  For those drugs where both
efficacy and toxicity are closely related
to plasma concentrations, the
recommended regimens should be seen
only as a guide to initial treatment;
subsequent treatment must be
adjusted according to clinical response
and plasma concentration.
The total daily maintenance dose
may need to be reduced and this is
done by either reducing the size of the
dose itself or by increasing the dosage
interval.  For some drugs, if the size of
the maintenance dose is reduced, it
will be important to give a loading
dose if an immediate effect is required.
When a patient is given a regular dose,
it takes more than five times the half-
life to achieve steady state plasma
concentrations.  The plasma half-life of
drugs excreted by the kidney is
prolonged in renal failure and so the
reduced dose may take many days to
achieve a therapeutic plasma
concentration.  The loading dose
should usually be the same size as the
initial dose of a patient with normal
renal function.6
Calculating
creatinine clearance
The severity of renal impairment is
expressed in terms of glomerular
filtration rate and is usually measured
by the creatinine clearance.  The
equation generally quoted to calculate
creatinine clearance is the Cockcroft &
Gault equation and uses serum
creatinine.  Using serum creatinine to
calculate creatinine clearance assumes
that renal function and serum
creatinine are stable.
CrCl= F x (140 - age) x (weight in Kg)
/ plasma creatinine (micromol/L)3,4
where F = 1.04 in females and 1.23 in
males.
In cases of obesity, oedematous
patients and patients with ascites, the
ideal body weight must be used.  The
equation cannot be used in children,
pregnancy, marked catabolism or
rapidly changing renal function,
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while in patients with muscle wasting
diseases, use of the equation will lead
to an overestimation of the creatinine
clearance.
Drug dosing in renal
replacement therapies
When prescribing a drug for a
patient on a renal replacement therapy,
one must be aware of the factors
involved which will affect the clearance
of the drug and whether a drug is
actually dialysed or not.  The summary
of product characteristics, which is the
detailed product information supplied
by the drug marketing authorization
holder, usually contains details of
dosage regimens according to the type
of replacement therapy the patient is
on.  Clearance of the drug may be
affected by factors such as drug
characteristics and dialysis
characteristics.  Highly protein bound
drugs and very large molecules are less
likely to be removed.  Dialysis solutions
are aqueous so water-soluble drugs are
preferentially eliminated.  Lipid-soluble
drugs tend to have larger volumes of
distribution and so concentrations in
plasma are comparatively small.3
Dialysis characteristics such as flow
rate, composition of dialysate, type of
dialyser membrane and duration of
procedure all affect drug removal.7
No renal replacement therapy is as
effective as the normal kidney, so the
doses used will never be larger than
those recommended in normal renal
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